GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (XSWX:NOVNEE) » Definitions » EBITDA Margin %

Novartis AG (XSWX:NOVNEE) EBITDA Margin % : 38.48% (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Novartis AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Novartis AG's EBITDA for the three months ended in Mar. 2024 was CHF4,144 Mil. Novartis AG's Revenue for the three months ended in Mar. 2024 was CHF10,770 Mil. Therefore, Novartis AG's EBITDA margin for the quarter that ended in Mar. 2024 was 38.48%.


Novartis AG EBITDA Margin % Historical Data

The historical data trend for Novartis AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG EBITDA Margin % Chart

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.08 34.49 70.30 33.78 39.12

Novartis AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.55 34.57 40.40 35.51 38.48

Competitive Comparison of Novartis AG's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Novartis AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Novartis AG's EBITDA Margin % falls into.



Novartis AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Novartis AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=15786.924/40351.568
=39.12 %

Novartis AG's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=4144.43/10769.832
=38.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novartis AG  (XSWX:NOVNEE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Novartis AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Novartis AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (XSWX:NOVNEE) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (XSWX:NOVNEE) Headlines

No Headlines